Abstract
This study aims to clarify the potential role of Raf-1 kinase in cerebral vasospasm (CVS) and early brain injury (EBI) after subarachnoid hemorrhage (SAH). Two experimental SAH models in rats, including cisterna magna double injection model for CVS study and prechiasmatic cistern single injection model for EBI study, were performed in this research. As a specific inhibitor of Raf-1, BAY 43-9006 was used in this study. In CVS study, time course study showed that the basilar artery exhibited vasospasm after SAH and became most severe at day 5, and the phosphorylation of Raf-1 had the same trends, while both vasospasm and the phosphorylation of Raf-1 induced by SAH were inhibited by BAY 43-9006 treatment. In addition, BAY 43-9006 treatment significantly reversed the phosphorylation of ERK1/2 and the activation of NF-κB induced by SAH and decreased the messenger RNA (mRNA) levels of IL-6 and IL-1β. In EBI study, BAY 43-9006 treatment significantly suppressed the brain injury induced by SAH. Besides, BAY 43-9006 inhibited the phosphorylation of Raf-1 and ERK1/2; decreased the protein levels of COX-2, VEGF, and MMP-9; and reversed the activation of NF-κB induced by SAH. These results demonstrate that Raf-1 kinase contributes to CVS and EBI after SAH by enhancing the activation of the Raf-1/ERK1/2 and Raf-1/NF-κB signaling pathways, and that the inhibition of these pathways might offer new treatment strategies for CVS and EBI.
Keywords:
BAY 43-9006; Cerebral vasospasm; Early brain injury; Raf-1; Subarachnoid hemorrhage.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Basilar Artery / physiopathology
-
Basilar Artery / ultrastructure
-
Blood-Brain Barrier
-
Brain Damage, Chronic / enzymology*
-
Brain Damage, Chronic / etiology
-
Brain Edema / etiology
-
Cyclooxygenase 2 / biosynthesis
-
Cyclooxygenase 2 / genetics
-
Disease Models, Animal
-
Down-Regulation / drug effects
-
Interleukin-1beta / biosynthesis
-
Interleukin-1beta / genetics
-
Interleukin-6 / biosynthesis
-
Interleukin-6 / genetics
-
MAP Kinase Kinase Kinases / antagonists & inhibitors
-
MAP Kinase Kinase Kinases / physiology*
-
Male
-
Matrix Metalloproteinase 9 / biosynthesis
-
Matrix Metalloproteinase 9 / genetics
-
Mitogen-Activated Protein Kinase Kinases / biosynthesis
-
Mitogen-Activated Protein Kinase Kinases / genetics
-
NF-kappa B / antagonists & inhibitors
-
NF-kappa B / metabolism
-
Nerve Tissue Proteins / antagonists & inhibitors
-
Nerve Tissue Proteins / genetics
-
Nerve Tissue Proteins / physiology*
-
Niacinamide / analogs & derivatives
-
Niacinamide / pharmacology
-
Phenylurea Compounds / pharmacology
-
Phosphorylation / drug effects
-
Protein Kinase Inhibitors / pharmacology
-
Protein Processing, Post-Translational / drug effects
-
Proto-Oncogene Proteins c-raf
-
RNA, Messenger / biosynthesis
-
Rats
-
Rats, Sprague-Dawley
-
Signal Transduction / drug effects
-
Sorafenib
-
Subarachnoid Hemorrhage / complications*
-
Vascular Endothelial Growth Factor A / biosynthesis
-
Vascular Endothelial Growth Factor A / genetics
-
Vasospasm, Intracranial / enzymology*
-
Vasospasm, Intracranial / etiology
Substances
-
Interleukin-1beta
-
Interleukin-6
-
NF-kappa B
-
Nerve Tissue Proteins
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
RNA, Messenger
-
Vascular Endothelial Growth Factor A
-
vascular endothelial growth factor A, rat
-
Niacinamide
-
Sorafenib
-
Cyclooxygenase 2
-
Ptgs2 protein, rat
-
Proto-Oncogene Proteins c-raf
-
Raf1 protein, rat
-
MAP Kinase Kinase Kinases
-
Mitogen-Activated Protein Kinase Kinases
-
Matrix Metalloproteinase 9
-
Mmp9 protein, rat